Betapharm's acquisition by Dr Reddy's LabPresentation Transcript
Dr. Reddy’s Labs acquires Betapharm for $ 560mn. Mumbai. In what is seen as India Inc’s first major M&A in pharma sector, DRL acquired 100% stake in Germany based Betapharm for $560mn. The stock closed a whopping 9.3 % up on the news.
- The Acquirer
Among the largest domestic pharma companies in India
Annual turnover of over INR 4900 Cr.
Annual PAT of INR 438 Cr.
Approved by USFDA , MHRA (UK)
Formulations make 37% of company’s product mix; generic products account for 13%
- The Target
Fourth largest generic pharma company in Germany
EBITDA margins between 24 – 26%
Portfolio of over 145 products
Sticker Price of €480 mn. from PE firm 3i
Revenues of € 165 mn.
2.9X revenues and 12X EBITDA
The transaction was funded using a combination of DRL’s internal cash reserves and committed credit facilities
Access to lucrative German generic drug market
DRL is likely to leverage its product development skills and low-cost manufacturing in India to boost Betapharm’s EBITDA margins
Help DRL realize its ambition of becoming a US$1 billion mid-size global pharmaceutical company by 2008
A Sweet Pill ?
With assumptions and available industry data, ICICI did a quick NPV valuation of Betapharm and arrived at a value of €550-560 million assuming WACC of 12% and a sustainable growth rate of 5%. The payback period was seen to be 6-7 years.
The deal was seen as an Accretive Acquisition.
Stock jumps on acquisition news correction in prices BSE Code - 500124 Face value - Rs. 5.00 Promoter holding- 26.40% 52 week H/L – 739 (16 June 08)/ 387 (18 Nov 08)
Particulars 2005-06 2006-07 2007-08 Sales (in Rs. Cr.) 2,095.51 3,828.04 3,330.66 Cost of Sales (in Rs. Cr.) 1,686.19 2,455.91 2,761.19 PAT (in Rs. Cr.) 211.12 1,176.86 475.22 EPS( in Rs.) 27.53 70.09 28.26 OPM % 12.61 31.69 15.06
Betapharm booked FY losses in ’08, ‘09
Raw materials problems in Mexico
Absence of upsides (revenues arising out of marketing exclusivity of authorised generics)
Betapharm contributing INR 2.6 bn.
New launches seem to have helped Betapharm improve its performance compared to that in Q1 ( 20 more in pipeline)
It was impacted due to price cuts (upto 20%) and stock adjustments.
Fierce competitive bidding from various generic companies has increased the acquisition cost for DRL and extended the payback period
Acquisitions contributed Rs3.9b (20% of sales) with Betapharm contributing Rs2.6b and Mexico acquisition Rs1.4b. New launches seem to have helped Betapharm improve its performance compared to that in 1Q wherein it was impacted due to price cuts and stock adjustments. Overall gross margins (GPM) were at 41% compared to 51% for 2QFY06. We believe that authorized generics and the Mexico acquisition have pulled down overall margins as the company’s core business enjoys about 50-53% GPM. We believe that authorized generics would be enjoying GPM of only 20%. Betapharm GPM has improved to 58% (53% in 1Q) while API GPM has also improved to 41% contributing positively to overall GPM
A case of wrong prescription?
“ We see our investment in Betapharm as a key strategic initiative towards becoming a mid-sized global pharmaceutical company with strong presence in all key pharmaceutical markets. Betapharm has created a strong growth platform and is well positioned for the future and we are looking forward to partner with them in building a strategic presence in Europe."